Newborn and Infant Nursing Reviews
Volume 8, Issue 1 , Pages 18-29 , March 2008

Disorders of Fatty Acid Oxidation in the Era of Tandem Mass Spectrometry in Newborn Screening

  • Sandra A. Banta-Wright, RNC, MN, NNP

      Affiliations

    • Child Development and Rehabilitation Center, Oregon Health and Science University, Portland, OR
    • Oregon Institute on Disability and Development, Child Development and Rehabilitation Center, Oregon Health and Science University, Portland, OR
    • Corresponding Author InformationAddress correspondences to Sandra A. Banta-Wright, RNC, MN, NNP, LEND Training Program, Child Development and Rehabilitation Center, Oregon Health and Science University, 707 SW Gaines Road, Portland, OR 97239. Tel.: +1 503 703 1895.
    • ,
  • Kathleen C. Shelton, PhD, PNP

      Affiliations

    • Child Development and Rehabilitation Center, Oregon Health and Science University, Portland, OR
    • ,
  • Michael J. Bennett, PhD, FRCPath, FACB

      Affiliations

    • University of Pennsylvania, Evelyn Willing Bromley Endowed Chair in Clinical Laboratory Medicine and Pathology
    • Metabolic Disease Laboratory, The Children's Hospital of Philadelphia, Philadelphia, PA

References 

  1. Guthrie R, Susi A. A simple phenylalanine method for detecting PKU in large, populations of newborn infants. Pediatrics. 1963;32:338–343
  2. Beasley M, Costello P, Smith I. Outcome of treatment in young adults with phenylketonuria detected by routine neonatal screening between 1964 and 1971. Q J Med. 1994;87:155–160
  3. MacGready RA, Hussey MG. Newborn phenylketonuria detection program in Massachusetts. Am J Public Health. 1964;54:2075
  4. National Research Council , Committee for the study of inborn errors of metabolism . Genetic screening: programs, principles, and research. Washington, DC: National Academy of Science; 1975;
  5. Newborn Screening Task Force . Serving the family from birth to the medical, home: a report from the newborn screening task force. Pediatrics. 2000;106:S383–S427
  6. Paul DB. The history of phenylketonuria screening in the US. In:  Holtzman NA,  Watson MS editor. Promoting safe and effective genetic testing in the United States: final report of the Task Force on Genetic Testing. Bethedsa (MD): National Institute of Health; 1997;
  7. President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research . Screening and counseling for genetic conditions: a report on the ethical, social and legal implications of genetic screening and counseling, and education programs. Washington DC: Government Printing Office; 1983;
  8. Wilson JMG, Jungner F. Principles and practice of screening for disease (Public Health Paper #34). Geneva: World Health Organization; 1968;
  9. American Academy of Pediatrics . Issues in newborn screening. Pediatrics. 1992;89:135–146
  10. Therrell BL, Panny SR, Davidson A, et al. U.S. newborn screening system, guidelines: statement of the Council of Regional Networks for Genetic Services. Screening. 1992;1:135–147
  11. Comeau AM, Hsu HW, Schwerzlwe M, et al. Detection of HIV in specimens from newborn screening programs. N Engl J Med. 1992;326:1703
  12. Schoen EJ, Black S, Cohen D, et al. Screening for neonatal toxoplasmosis. N Engl J Med. 1994;331:1456–1458
  13. Postellon DC. Screening for congenital hypothyroidism. J Pediatr. 1981;9:170–171
  14. Levy HL, Hammersen G. Newborn screening for galactosemia and other galactose metabolic defects. J Pediatr. 1978;92:871–877
  15. Waggoner DD, Buist NR, Donnell GN. Long-term prognosis in galactosaemia: results of a survey of 350 cases. J Inherit Metab Dis. 1990;13:802–818
  16. Millington DS, Roe CR, Maltby DA. Application of high resolution fast atom bombardment and constant B/E ration linked scanning to the identification and analysis of acylcarnitines in metabolic disease. Biomed Mass Spectrom. 1984;11:236–241
  17. Millington DS, Kodo N, Norwood DL, Roe CR. Tandem mass spectrometry: a new method for acylcarnitine profiling with potential for neonatal screening for inborn errors of metabolism. J Inherit Metab Dis. 1990;13:321–324
  18. Millington DS, Koeberl D. Metabolic screening in the newborn. Growth Genet Horm. 2003;19:33–38
  19. Zytkovicz TH, Fitzgerald EF, Marsden D, et al. Tandem mass spectrometric analysis for amino, organic, and fatty acid disorders in newborn dried blood spots: a two year summary from the New England Newborn Screening Program. Clin Chem. 2001;47:1945–1955
  20. Rashed MS, Rahbeeni Z, Ozand PT. Application of electrospray tandem mass spectrometry to neonatal screening. Semin Perinatol. 1999;23:183–193
  21. Millington DS, Terade N, Chace DH, et al. The role of tandem mass spectrometry in the diagnosis of fatty acid oxidation disorders. In:  Coates PM,  Tanaka K editor. New development in fatty acid oxidation: proceedings of the second International Symposium on clinical, biochemical, and molecular aspects of fatty acid oxidation. New York: Wiley-Liss; 1991;p. 339–354
  22. Chace DH, Millington DS, Terada N, et al. Rapid diagnosis of phenylketonuria by quantitative analysis for phenylalanine and tyrosine in neonatal blood spots by tandem mass spectrometry. Clin Chem. 1993;39:66–71
  23. Schmidt-Sommerfeld E, Penn D, Duran M, et al. Detection of inborn errors of fatty acid oxidation from acylcarnitine analysis of plasma and blood spots with radioisotopic exchange-high-performance liquid chromatographic method. J Pediatr. 1993;122:708–714
  24. Van Hove JL, Zhang W, Kahler SG, et al. Medium-chain acyl-CoA dehydrogenase (MCAD) deficiency: diagnosis by acylcarnitine analysis in blood. Am J Hum Genet. 1993;52:958–966
  25. Chace DH, Hillman SL, Millington DS, et al. Rapid diagnosis of maple syrup urine disease in blood spots from newborns by tandem mass spectrometry. Clin Chem. 1995;41:62–68
  26. Millington DS. Tandem mass spectrometry in clinical diagnosis. In:  Blau N,  Duran M,  Blaskovics ME,  Gibson KM editor. Physician's guide to the laboratory Diagnosis of metabolic diseases. 2nd ed.. Berlin, Germany: Springer; 2003;p. 57–85
  27. Sewell AC, Bohles HJ. Acylcarnitines in intermediary metabolism. Eur J Pediatr. 1995;154:871–877
  28. Carter AL, Abney TO, Lapp DF. Biosynthesis and metabolism of carnitine. J Child Neurol. 1995;10(Suppl 2):S3–S7
  29. Chace DH, Hillman SL, Van Hove JL, et al. Rapid diagnosis of MCAD deficiency: quantitative analysis of octanoylcarnitine and other acylcarnitines in newborn blood spots by tandem mass spectrometry. Clin Chem. 1997;43:2108–2113
  30. Ziadeh R, Hoffman EP, Finegold DN, et al. Medium chain acyl-CoA dehydrogenase deficiency in Pennsylvania: neonatal screening shows high incidence and unexpected mutation frequencies. Pediatr Res. 1995;37:675–678
  31. American College of Medical Genetics . Standardization of outcomes and guidelines for state newborn screening program. Fed Regist. 2005;70:Department of Health and Human Services. Available at: www.mchc.hrsa.gov/screening/summary.htm.[Retrieved July 30, 2007]
  32. Bennett MJ. The enzymes of mitochondrial fatty acid oxidation. Clin Chim Acta. 1994;226:213–224
  33. Krebs HA. The history of the tricarboxylic acid cycle. Perspect Biol Med. 1970;14:154–170
  34. McGarry JD, Brown NF. The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis. Eur J Biochem. 1997;244:1–14
  35. Brown NF, Mullur RS, Subramanian I, et al. Molecular characterization of L-CPT I deficiency in six patients: insight into function of the native enzyme. J Lipid Res. 2001;42:1134–1142
  36. Bougneres PF, Saudubray JM, Marsac C, et al. Fasting hypoglycemia resulting from hepatic carnitine palmitoyltransferase deficiency. J Pediatr. 1981;98:742–746
  37. Bonnefont JP, Haas R, Wolff R, et al. Deficiency of carnitine palmitoyltransferase I. J Child Neurol. 1989;4:198–203
  38. Bougneres PF, Saudubray JM, Marsac C, et al. Decreased ketogenesis due to deficiency of hepatic carnitine acyltransferase. N Engl J Med. 1980;302:123–124
  39. Fingernut R, Roschinger W, Muntau AC, et al. Hepatic palmitoyltransferase I deficiency: acylcarnitine profiles in blood spots are highly specific. Clin Chem. 2001;47:1763–1768
  40. Prip-Buus C, Thuiller L, Abadi N, et al. Molecular and enzymatic characterization of a unique carnitine palmitoyltransferase 1A mutation in the Hutterite community. Mol Genet Metab. 2001;73:46–54
  41. Prasad C, Johnson JP, Bonnefont JP, et al. Hepatic carnitine palmitoyltransferase 1 (CPT1 A) deficiency in North American Hutterites (Canadian and American): evidence for a founder effect and results of a pilot study on a DNA based newborn screening program. Mol Genet Metab. 2001;73:55–63
  42. Seargeant LE, Stier A, Prasad C, et al. Preliminary evidence for high frequency of combined CPT 1 and CPT 2 mutations in the Canadian Inuit. In: IX International Congress on Inborn Errors of Metabolism, Brisbane, Australia, September 2-6, 2003. J Inherit Metab Dis. 2003;26(suppl 2):197
  43. Sinclair G, Waters PJ, Vallance H, et al. The dilemma of the CPT-1 P479L mutation in Canadian Inuit and First Nations Families. In: 6th International Congress on Fatty Acid Oxidation, Egmond aan Zee, the Netherlands, 21. 2005;
  44. Gillingham MB, Banta-Wright SA, Bennett MJ, et al. High incidence of the carnitine palmitoyltransferase-1A P479L variant identified in Alaska native infants by expanded newborn screening. In preparation.
  45. Roe CR, Ding J. Mitochondrial fatty acid oxidation disorders. In:  Scriver CR,  Beaudet AL,  Sly WS,  Valle D editor. The metabolic and molecular bases of inherited disease. 9th ed.. New York: McGraw-Hill; 2001;p. 2297–2326
  46. Maier EM, Leibl B, Roschinger W, et al. Population spectrum of ACADM genotypes correlated to biochemical phenotypes in newborn screening for medium-chain acyl-CoA dehydrogenase deficiency. Hum Mutat. 2005;25:443–452
  47. Chace DH, Kalas TA, Naylor EW. The application of tandem mass spectrometry in neonatal screening for inherited disorders of intermediary metabolism. Annu Rev Genomics Hum Genet. 2002;3:17–45
  48. Carpenter K, Wiley V, Sim KG, et al. Evaluation of newborn screening for medium chain acyl-CoA dehydrogenase deficiency in 275,000 babies. Arch Dis Child Fetal Neonatal Ed. 2001;85:F105–F109
  49. Sanders S, Janze N, Janetzky B, et al. Neonatal screening for medium acyl-CoA deficiency: high incidence in lower Saxony (northern Germany). Eur J Pediatr. 2001;160:318–319
  50. Kolvraa S, Gregersen N, Christensen E, Hobolth N. In vitro fibroblast studies in a patient with C 6-C 10 dicarboxylic aciduria: evidence for a defect in general acyl-CoA dehydrogenase. Clin Chim Acta. 1982;126:53–67
  51. Kidd JR, Matsubara Y, Castiglione CM, et al. The locus for the medium-chain acyl-coA dehydrogenase gene on chromosome 1 is highly polymorphic. Genomics. 1990;6:89–93
  52. Andresen BS, Sobrowolski SF, O'Reilly L, et al. Medium-chain acyl-CoA dehydrogenase (MCAD) mutations identified by MS/MS-based prospective screening of newborns differ from those observed in patients with clinical symptoms: identification and characterization of a new, prevalent mutation that results in mild MCAD deficiency. Am J Hum Genet. 2001;68:1408–1418
  53. Tajima G, Sakura N, Ono H, et al. Medium chain acyl-coA dehydrogenase deficiency found through newborn screening by tandem mass spectrometry in Japan. J Inherit Metab Dis. 2004;(Suppl 1):11
  54. Andresen BS, Bross P, Udvari S, et al. The molecular basis for medium-chain acyl-coA dehydrogenase (MCAD) deficiency in compound heterozygous patients: is there correlation between genotype and phenotype?. Hum Mol Genet. 1997;6:695–707
  55. Coates PM, Hale DE, Stanley CA, et al. Genetic deficiency of medium-chain acyl coenzyme a dehydrogenase: studies in cultured skin fibroblasts and peripheral mononuclear leukocytes. Pediatr Res. 1985;19:671–676
  56. Bennett MJ, Rinaldo P, Millington DS, et al. Medium chain acyl-coA dehydrogenase deficiency: postmortem diagnosis in case of sudden infant death and neonatal diagnosis of an affected sibling. Pediatr Pathol. 1991;11:889–895
  57. Rashad MS, Ozand PT, Bennett MJ, et al. Inborn errors of metabolism diagnosed in sudden death cases by acylcarnitine analysis of postmortem bile. Clin Chem. 1995;41(8 pt1):109–111
  58. Iafolla AK, Thompson RJ, Roe CR. Medium-chain acyl-coenzyme A dehydrogenase deficiency: clinical course in 120 affected children. J Pediatr. 1994;124:409–415
  59. Christodoulou J, Hoare J, Hammond J, et al. Neonatal onset of medium-chain acyl-coenzyme A dehydrogenase deficiency with confusing biochemical features. J Pediatr. 1995;126:65–68
  60. Wilcox RL, Nelson CC, Stenzel P, Steiner RD. Postmortem screening for fatty acid oxidation disorders by analysis of Guthrie cards with tandem mass spectrometry in sudden unexpected death in infancy. J Pediatr. 2002;141:833–836
  61. Emery JL, Variend S, Howat AJ, et al. Investigation of inborn errors of metabolism in unexpected infant deaths. Lancet. 1988;2:29–31
  62. Harpey JP, Charpentier C, Paturneau-Jouas M. Sudden infant death syndrome and inherited disorders of fatty acid b-oxidation. Biol Neonate. 1990;58(Suppl 1):70–80
  63. Treem WR, Stanley CA, Goodman SI. Medium-chain acyl-CoA dehydrogenase deficiency: metabolic effects and therapeutic efficacy of long-term l-carnitine supplementation. J Inherit Metab Dis. 1989;12:112–119
  64. Stumpf DA, Parker WD, Angelini C. Carnitine deficiency, organic acidemias and Reye's syndrome. Neurology. 1985;35:1041–1045
  65. Roe CR, Millington DS, Kahler SG, et al. Carnitine homeostasis in the organic acidurias. In:  Tanaka K,  Coates PM editor. Fatty acid oxidation: clinical, biochemical and molecular aspects. New York: Alan R. Liss; 1990;p. 382–402
  66. Rinaldo R, Schmidt-Sommerfeld E, Posca AP, et al. Effect of treatment with glycine and l-carnitine in medium-chain acyl-coenzyme a dehydrogenase deficiency. J Pediatr. 1993;122:580–584
  67. Spieketkoetter U, Tokunaga C, Wendel U, et al. Tissue carnitine homeostasis in very-long-chain acyl-CoA dehydrogenase-deficient mice. Ped Res. 2005;57:760–764
  68. Spiekerkoetter U, Sun B, Zytkovicz T, et al. MS/MS-based newborn and family screening detects asymptomatic patients with very-long-chain acyl-CoA dehydrogenase deficiency. J Peds. 2003;143:335–342
  69. Bertran C, Largilliere C, Zabot MT, et al. Very-long-chain acyl-coA dehydrogenase deficiency: identification of a new inborn error of mitochondrial fatty acid oxidation in fibroblasts. Biochim Biophys Acta. 1993;1180:327–329
  70. Aoyama T, Uchida Y, Kelley RI, et al. A novel disease with deficiency of mitochondrial very-long-chain acyl-CoA dehydrogenase. Biochem Biophys Res Commun. 1993;191:1369–1372
  71. Izai K, Uchida Y, Orii T, Hashimoto . Novel fatty acid beta-oxidation enzymes in rat liver mitochondria. I. Purification and properties of very-long-chain acyl-coenzyme A dehydrogenase. J Biol Chem. 1992;267:1027–1033
  72. Aoyama T, Ueno I, Kamijo T, Hashimoto T. Rat very-long-chain acyl-CoA dehydrogenase, a novel mitochondrial acyl-CoA dehydrogenase gene product, is a rate-limiting enzyme in long-chain fatty acid beta-oxidation system. cDNA and deduced amino acid sequence and distinct specificities of the cDNA-expressed protein. J Biol Chem. 1994;269:19088–19094
  73. Hale DE, Bennett MJ. Fatty acid oxidation disorders: a new class of metabolic diseases. J Pediatr. 1992;121:1–11
  74. Yamaguchi S, Idno Y, Coates PM, et al. Identification of very-long-chain acyl-Coa dehydrogenase deficiency in three patients previously diagnosed with long-chain acyl-CoA dehydrogenase deficiency. Ped Res. 1993;34:111–113
  75. Wood JC, Magera MJ, Rinaldo P, et al. Diagnosis of very long chain acyl-dehydrogenase deficiency from an infant's newborn screening card. Pediatrics. 2001;108:E19
  76. Touma EH, Rashed MS, Vianey-Saban C, et al. A severe genotype with favourable outcome in very long chain acyl-coA dehydrogenase deficiency. Arch Dis Child. 2001;84:58–60
  77. Yoon N, Strauss AW, Yoo HW. Sudden death in a Korean infant with very-long-chain acyl-CoA dehydrogenase deficiency. J Inherit Metab Dis. 2001;24:407–408
  78. Bonnett D, Martin D, de Lonlay P, et al. Arrhythmias and conduction defects as presenting symptoms of fatty acid oxidation disorders in children. Circulation. 1999;100:2248–2253
  79. Hahn SH, Lee EH, Jung JW, et al. Very long chain acyl coenzyme A dehydrogenase deficiency in a 5-month-old Korean boy: identification of a novel mutation. J Peds. 1999;135:250–253
  80. Boles RG. Very long-chain acyl-CoA dehydrogenase deficiency in an infant presenting with massive hepatomegaly. J Inherit Metab Dis. 2002;25:315–316
  81. Gregersen N, Andresen BS, Corydon MJ, et al. Mutation analysis in mitochondrial fatty acid oxidation defects: exemplified by acyl-CoA dehydrogenase deficiencies, with special focus on genotype-phenotype relationship. Human Mutat. 2001;12:169–189
  82. Cox KL, Hamm DA, Millington DS, et al. Gestational, pathologic and biochemical differences between very long-chain acyl-CoA dehydrogenase deficiency and long-chain acyl-CoA dehydrogenase deficiency in the mouse. Hum Mol Genet. 2001;10:2069–2077
  83. Andresen BS, Olpin S, Poorthuis BJHM, et al. Clear correlation of genotype with disease phenotype in very-long-chain acyl-CoA dehydrogenase deficiency. Am J Hum Genet. 1999;64:479–494
  84. Andresen BS, Dobrowolski SF, O'Reilly L, et al. Medium-chain acyl-CoA dehydrogenases (MCAD) mutations identified by MS/MS based prospective screening of newborns differ from those observed in patients with clinical symptoms: identification and characterization of a new, prevalent mutation that results in mild MCAD deficiency. Am J Hum Genet. 2001;68:1408–1418
  85. Gregersen N, Andresen BS, Bross P, et al. Molecular characterization of medium-chain acyl-CoA dehydrogenase (MCAD) deficiency: identification of a lys329 to glu mutation in the MCAD gene and expression of inactive mutant protein in E coli. Hum Genet. 1991;86:545–551
  86. Cox GF, Souri M, Aoyama T, et al. Reversal of severe hypertrophic cardiomyopathy and an excellent neurophysiologic outcome in very-long-chain acyl-coenzyme A dehydrogenase deficiency. J Pediatr. 1998;133:247–253
  87. Spiekerkotter U, Schwahn B, Korall H, et al. Very-long-chain acyl-coenzyme A dehydrogenase (VLCAD) deficiency: monitoring of treatment by carnitine/acylcarnitine analysis in blood spots. Acta Paediatr. 2000;89:492–495
  88. National Newborn Screening and Genetic Resources Center (NNSGRC). Availableat http://genes-r-us.uthscsa.edu/resources/newborn/screenstatus.htm.[Retrieved July 30, 2007]

☆ This work was supported by T-73 MC000034, a training grant from the Maternal-Child Health Bureau for Leadership, Education in Neurodevelopmental and Related Disabilities (LEND) Program.

PII: S1527-3369(07)00194-8

doi: 10.1053/j.nainr.2007.12.014

Newborn and Infant Nursing Reviews
Volume 8, Issue 1 , Pages 18-29 , March 2008

Article Tools

* Image Usage & Resolution